Project Grant R01EY036137
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Teardx, LLC will fund the development of a rapid, point-of-care diagnostic test to accurately detect ocular herpes simplex virus (HSV-1) infections. The project aims to create a user-friendly, minimally invasive sampling tool and assay that can be used by eye specialists and urgent care clinicians to quickly screen for active HSV-1 infections, which are a leading cause...
- This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) aims to develop and validate a novel Adaptive Optics Optical Coherence Tomography (AO-OCT) system tailored for high-resolution, wide-field retinal imaging in small animal models, specifically mice. The $305,000 project, awarded on September 1, 2025, with an expected completion date of August 31, 2026, has two key objectives: Develop and optimize a portable AO-OCT system with enhanced imaging capabilities...
- This Project Grant award from the National Eye Institute's Vision Research program (CFDA 93.867) provides $179,964 to the University of California, Irvine (UCI) to develop innovative biomarkers for optic neuropathies using deep learning-based analysis of optical coherence tomography (OCT) imagery. The project aims to overcome limitations of current OCT-based diagnostics by employing advanced computational techniques like deep learning, neural fields, and geometric modeling to enhance the...
- The National Eye Institute (NEI), under the U.S. Department of Health and Human Services, awarded a $693,423 Project Grant on September 15, 2025 to the University of Mississippi Medical Center (UMMC) to develop a multivalent antibody cocktail for the treatment of bacterial endophthalmitis. The goal of this 1-year project is to translate prior research on ocular microbiology into a new drug that can be used in conjunction with antibiotics to combat damage and loss of retinal function caused by...
- This Project Grant award from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), is providing $306,462 to Ifocus Imaging LLC to develop a software platform called OCT-ART-DR. The platform will automate the diagnosis and staging of diabetic retinopathy using optical coherence tomography angiography (OCTA) imaging and artificial intelligence. The key products to be delivered under this award include: 1) Improved AI-based segmentation of OCTA image...
- The National Eye Institute (NEI) awarded Kineolabs, Inc. a $300,001 Project Grant under the Vision Research program (CFDA 93.867) to develop a portable, low-cost line-scan swept-source optical coherence tomography (LS-SS-OCT) imaging system. The objective is to use this LS-SS-OCT technology for early detection and monitoring of age-related macular degeneration (AMD), diabetic retinopathy, and other eye diseases. The project aims to make OCT imaging more affordable and accessible to reduce the...
- This Project Grant award from the National Eye Institute (NEI), under the federal Vision Research program (CFDA 93.867), aims to advance the development of the drug filociclovir (FCV) for the treatment of adenoviral conjunctivitis and epidemic keratoconjunctivitis. The $674,963 award to Microbiotix, Inc. will fund the completion of key preclinical activities, including finalizing the eye drop formulation, conducting IND-enabling toxicology studies in rabbits and rats, and completing regulatory...
- The National Eye Institute (NEI) awarded a $412,285 Project Grant under the Vision Research program (CFDA 93.867) to Oregon Health & Science University (OHSU) to validate an advanced transepithelial corneal collagen crosslinking (CXL) technology. The goal is to develop a more effective CXL procedure that can strengthen the cornea without requiring removal of the surface epithelium, which often leads to complications. The key products and services to be delivered include: Constructing an...
- This $745,607 Project Grant award from the National Eye Institute (CFDA 93.867 Vision Research) supports the development of the RETIVUE ENTIREEYE, a handheld, high-resolution, non-contact, single-image, widefield retinal screening camera for premature and healthy newborn babies. The device utilizes a novel all-digital, no moving parts scanning light module to capture a seamless, high-quality, diagnostic ultra-widefield image of the entire baby eye in a single shot. This technology has the...
- This Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $305,000.00 to Resonantia Diagnostics, Inc. to develop a transformative diagnostic platform for rapid identification and antimicrobial susceptibility testing of pathogens. The project aims to achieve three key technical objectives: (1) demonstrate accurate antimicrobial susceptibility testing at very low pathogen loads, (2) validate testing...
RAPID DIAGNOSIS OF OCULAR INFECTIONS USING A SENSITIVE AND HIGHLY MULTIPLEXED BROAD PATHOGEN DETECTION ASSAY - PROJECT SUMMARY TIMELY AND ACCURATE DIAGNOSIS OF OCULAR INFECTIONS IS CRITICAL TO SUPPORT EARLY EFFECTIVE THERAPY AND SAVE VISION. SERIOUS INFECTIONS SUCH AS INFECTIOUS KERATITIS, UVEITIS AND ENDOPHTHALMITIS ARE LEADING CAUSES OF BLINDNESS GLOBALLY. THESE INFECTIONS ARE CAUSED BY A WIDE RANGE OF PATHOGENS, WHICH CAN OFTEN PRESENT WITH OVERLAPPING FEATURES AND ARE DIFFICULT TO DIFFERENTIATE CLINICALLY. LABORATORY-BASED DIAGNOSIS IS AN IMPORTANT COMPONENT OF CLINICAL MANAGEMENT TO GUIDE EFFICIENT DEPLOYMENT OF THERAPIES. HOWEVER, BECAUSE CURRENT METHODS EMPLOYED FOR PATHOGEN DETECTION ARE OUTDATED, TIME-CONSUMING AND LACK SENSITIVITY, PATIENTS CAN BE TREATED FOR PROLONGED PERIODS WITH COMBINATIONS OF EMPIRICAL BROAD-SPECTRUM THERAPIES THAT ARE NOT TAILORED FOR AN INDIVIDUAL, MAY BE INEFFECTIVE, CAUSE NEEDLESS OCULAR TOXICITY, AND ARE BECOMING COMPROMISED BY THE EMERGENCE OF ANTIMICROBIAL RESISTANCE. RAPID PRECISION DIAGNOSTIC TESTS ARE CRITICALLY NEEDED TO HELP GUIDE THERAPY AND IMPROVE PATIENT OUTCOMES. TO ADDRESS THIS CRITICAL AND URGENT NEED, WE ARE DEVELOPING NOVEL AND HIGHLY MULTIPLEXED TARGETED ASSAYS FOR COMPREHENSIVE DETECTION OF PATHOGENS FROM OCULAR SPECIMENS WITH HIGH ACCURACY AND SPEED. THIS INNOVATIVE APPROACH LEVERAGES THE ADVANTAGES OF THE CUTTING-EDGE NANOSTRING TECHNOLOGY, WHICH ENABLES RAPID AND SIMULTANEOUS DETECTION AND QUANTIFICATION OF HUNDREDS OF DIFFERENT DNA OR RNA MOLECULES WHILE MAINTAINING EXCELLENT SENSITIVITY PER TARGET. IN PRELIMINARY STUDIES, WE DEMONSTRATED THAT OUR NOVEL DIAGNOSTIC APPROACH CAN DETECT THE MOST IMPORTANT ETIOLOGIES OF SIGHT-THREATENING INFECTIONS IN A HIGHLY MULTIPLEXED FORMAT, WITH HIGH SENSITIVITY AND SPECIFICITY, AND IN A TIMELY MANNER, REDUCING THE TIME FROM SAMPLE TO ANSWER FROM DAYS TO 12 HOURS. WITH PROOF-OF-PRINCIPLE ESTABLISHED AND ANALYTICAL VALIDATIONS THOROUGHLY PERFORMED FOR AN INITIAL PANEL ABLE TO SIMULTANEOUSLY DETECT 48 TARGETS IN A SINGLE REACTION, WE ARE NOW AIMING TO 1) FURTHER DEVELOP, EXPAND, AND VALIDATE OUR PANEL WITH THE GOAL OF COVERING ADDITIONAL PATHOGENS OF RELEVANCE IN KERATITIS WITH BROADER GEOGRAPHICAL COVERAGE AND APPLICABILITY, AND 2) LAY THE GROUNDWORK NECESSARY TO TRANSLATE THIS TECHNOLOGY INTO PRACTICE AND FACILITATE ITS CLINICAL IMPLEMENTATION BY PERFORMING EXTENSIVE CLINICAL VALIDATIONS USING OUR EXISTING LARGE BIOREPOSITORIES OF SPECIMENS COLLECTED FROM PATIENTS PRESENTING WITH INFECTIOUS KERATITIS, UVEITIS AND ENDOPHTHALMITIS, AND ADDITIONAL SAMPLES THAT WILL CONTINUE TO BE COLLECTED IN THE FIRST YEARS OF THE PROJECT. THIS PROPOSAL WILL RESULT IN A TECHNICALLY NOVEL AND CLINICALLY USEFUL DIAGNOSTIC APPROACH THAT WILL ADVANCE THE DIAGNOSIS OF INFECTIONS ASSOCIATED WITH GREAT OCULAR MORBIDITY GLOBALLY, USING AN ASSAY THAT CAN DETECT ~95% OF THE ETIOLOGIES OF SIGHT-THREATENING INFECTIONS IN ONLY 12 HOURS, AND WITH HIGH ACCURACY, INCLUDING DIFFICULT TO CULTURE AND POTENTIALLY UNCULTURABLE PATHOGENS, MAKING A SINGLE-REACTION DIAGNOSTIC TEST COMPREHENSIVE AT AN UNPRECEDENTED LEVEL. THIS IS EXPECTED TO TRANSFORM OCULAR INFECTION TREATMENT BY SUPPORTING PROMPT INITIATION OF THERAPY WITH AN EFFECTIVE DRUG AT EARLY STAGES OF THE INFECTION, HELPING TO SAVE VISION AND PROMOTING ANTIMICROBIAL DE-ESCALATION TO REDUCE THE OVERUSE OF EMPIRICAL THERAPIES AND LIMIT THE SPREAD OF ANTIMICROBIAL RESISTANCE.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $425.0k | 7/7/25 | ||
| Not listed | $425.0k | 4/11/24 |